Vitafoods Insights is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Podcast: Cannabinoids and Epilepsy

<p style="margin: 0cm 0cm 8pt;">Europe is set to become a key market for a number of new cannabinoid-infused nutraceutical products targeting the nutrition industry.</p>

Europe is set to become a key market for a number of new cannabinoid-infused nutraceutical products targeting the nutrition industry, and the European Industrial Hemp Association has said there’s an ‘urgent need for proper legislation’. Meanwhile, we’re seeing more and more anecdotal evidence about how cannabinoids seem to alleviate the symptoms of epilepsy yet there’s little research supporting their efficacy. To debate cannabinoids in the European market and ‘Hippie’s Disappointment’, we’re joined by Gemma Mills, Sales Executive at Informa, to interview Matt Storey, director of global business development at CW Hemp.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish